Scholar Rock Holding buy Lifesci Capital
Start price
04.06.25
/
50%
€27.00
Target price
04.06.26
-
Performance (%)
42.33%
End price
05.06.26
€38.43
Summary
This prediction ended on 05.06.26 with a price of €38.43. The BUY prediction by Lifesci_Capital for Scholar Rock Holding saw massive gains of 42.33%. Lifesci_Capital has 50% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Scholar Rock Holding | 16.642% | 16.642% | 56.895% |
| iShares Core DAX® | -1.358% | -2.165% | 2.078% |
| iShares Nasdaq 100 | -3.700% | -1.162% | 32.596% |
| iShares Nikkei 225® | -2.512% | 7.930% | 58.269% |
| iShares S&P 500 | -1.662% | -0.698% | 22.962% |
Comments by Lifesci_Capital for this prediction
In the thread Scholar Rock Holding diskutieren
Scholar Rock Holding Co. (NASDAQ: SRRK) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Ratings data for SRRK provided by MarketBeat
In the thread Trading Scholar Rock Holding
Die von Lifesci_Capital gewählte maximale Laufzeit wurde überschritten